Ivytan AB, which is indirectly owned by EQT and Lyftet Holding, has made a cash offer for Swedish biotechnology firm Q-Med valuing the business at SEK 3.9bn. The bid is priced at SEK 39 per Q-Med share - a 24% premium to the closing price on 31 October.
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater